Drug Trials News for June 2017

Roche presents new data further to characterise ocrelizumab in multiple measures of disease progression in relapsing and primary progressive multiple sclerosis Roche presents new data further to characterise ocrelizumab in multiple measures of disease progression in relapsing and primary progressive multiple sclerosis

Ocrelizumab increased the number of patients with relapsing MS (RMS) and primary progressive MS (PPMS) who maintained No Evidence of Progression or Active Disease (NEPAD) versus Rebif® (interferon beta-1a) in RMS and placebo in PPMSOcrelizumab significantly reduced the risk of RMS and PPMS patients requiring mobility aids versus an active comparator (RMS) and placebo (PPMS)In PPMS patients, ocrelizumab reduced the risk of more severe forms of disability progression versus placebo
23 June, 2017